Laboratory Co. of America Holdings (NYSE:LH) EVP Der Vaart Sandra D. Van Sells 259 Shares

Laboratory Co. of America Holdings (NYSE:LHGet Free Report) EVP Der Vaart Sandra D. Van sold 259 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $222.06, for a total value of $57,513.54. Following the completion of the sale, the executive vice president now owns 7,637 shares of the company’s stock, valued at approximately $1,695,872.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Laboratory Co. of America Stock Down 0.1 %

Shares of Laboratory Co. of America stock opened at $222.59 on Friday. The company has a current ratio of 1.36, a quick ratio of 1.20 and a debt-to-equity ratio of 0.57. The business’s 50 day simple moving average is $223.49 and its 200-day simple moving average is $213.24. The stock has a market capitalization of $18.90 billion, a price-to-earnings ratio of 29.76 and a beta of 1.04. Laboratory Co. of America Holdings has a twelve month low of $174.20 and a twelve month high of $234.09.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.29%. The ex-dividend date of this dividend is Monday, February 26th. Laboratory Co. of America’s payout ratio is 38.50%.

Institutional Trading of Laboratory Co. of America

Several large investors have recently added to or reduced their stakes in LH. Roundview Capital LLC increased its position in Laboratory Co. of America by 1.6% in the 1st quarter. Roundview Capital LLC now owns 7,793 shares of the medical research company’s stock valued at $2,055,000 after acquiring an additional 124 shares during the period. LSV Asset Management increased its position in Laboratory Co. of America by 1.2% in the 1st quarter. LSV Asset Management now owns 34,800 shares of the medical research company’s stock valued at $9,175,000 after acquiring an additional 400 shares during the period. Synovus Financial Corp increased its position in Laboratory Co. of America by 105.7% in the 1st quarter. Synovus Financial Corp now owns 1,654 shares of the medical research company’s stock valued at $441,000 after acquiring an additional 850 shares during the period. Cibc World Market Inc. acquired a new stake in Laboratory Co. of America in the 1st quarter valued at approximately $213,000. Finally, Sei Investments Co. increased its position in Laboratory Co. of America by 18.9% in the 1st quarter. Sei Investments Co. now owns 89,167 shares of the medical research company’s stock valued at $23,543,000 after acquiring an additional 14,186 shares during the period. 89.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LH. JPMorgan Chase & Co. increased their price target on Laboratory Co. of America from $259.00 to $261.00 and gave the company an “overweight” rating in a report on Friday, November 17th. Evercore ISI initiated coverage on Laboratory Co. of America in a report on Friday. They issued an “in-line” rating and a $240.00 price target for the company. Barclays initiated coverage on Laboratory Co. of America in a report on Wednesday, January 3rd. They set an “equal weight” rating and a $222.00 target price on the stock. TheStreet raised Laboratory Co. of America from a “c+” rating to a “b-” rating in a report on Thursday, January 18th. Finally, Mizuho reduced their target price on Laboratory Co. of America from $257.00 to $230.00 and set a “buy” rating on the stock in a report on Tuesday, October 31st. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Laboratory Co. of America presently has a consensus rating of “Moderate Buy” and an average target price of $241.86.

Read Our Latest Report on LH

Laboratory Co. of America Company Profile

(Get Free Report)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development.

Featured Stories

Insider Buying and Selling by Quarter for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.